IMPACT BIOMEDICAL INC.

This Houston-based biotechnology company discovers and develops pharmaceutical and consumer health products targeting specialty therapeutic areas and wellness applications. The company operates four primary technology platforms: Linebacker, a series of small molecule electrophilically enhanced polyphenols being evaluated in oncology, inflammatory disorders, and neurology; Laetose technology, a sugar-inositol combination designed to modulate inflammatory and metabolic responses; functional fragrance formulations containing botanical ingredients with antimicrobial properties for use in personal care and household products; and Equivir/Equivir G, a polyphenol blend positioned as an antiviral ingredient for supplements and medications.

The company's business spans specialty biopharmaceuticals, antivirals, antimicrobials, and consumer healthcare segments. Its fragrance technology can be incorporated into diverse applications including insect repellents, detergents, lotions, shampoos, and fabrics, indicating a diversified commercialization strategy across multiple distribution channels and consumer categories.

Impact BioMedical operates at an early-stage scale with a two-person full-time workforce. The company is incorporated in Nevada and operates as a subsidiary of DSS, Inc. while maintaining headquarters in Houston, Texas. Geographic reach is primarily centered in the United States market.